🧪 Biotech startup valuation: Where science meets finance

In partnership with

Welcome back to Healthy Innovations! 👋

This week, I'm exploring something different from our usual healthcare innovations - the world of biotech valuation and startup investment. While I've partnered with biotech companies as a consultant and invested in a couple, I've never explored how investors actually determine the value of these startups.

While breakthrough medicines grab the headlines, understanding how to value biotech companies is crucial for founders, investors, and healthcare leaders alike. Every year, billions of dollars flow into biotech startups, making accurate valuation essential.

But how is it done?

In this issue, I'll take you with me as I break down how investors evaluate these companies and what they seek at each stage of development.

So, let's learn together and don’t forget to check out the two weird and wonderful highlights at the end (spoiler 🦖)!

The unique challenge of biotech valuation

Valuing a traditional company seems straightforward - you look at revenue and profits. But how do you assess a biotech startup that has no revenue, relies on promising but unproven technology in clinical trials, and might not bring a product to market for years - if at all?

Biotech startups face distinct challenges that make valuation particularly tricky:

• Extended timelines: 10-15 years from founding to market launch

• Regulatory hurdles: Approvals from FDA, EMA, and other agencies add uncertainty

• Binary outcomes: Success or failure often hinges on a single clinical trial

• High capital requirements: Up to $2 billion to develop a single drug

• Technical complexity: Specialized expertise needed to evaluate the science.

As one European venture capitalist aptly puts it, biotech valuation is "an art rather than a science," despite all the numbers involved.

How investors value biotech companies

Investors rely on several specialized methods:

1. Risk-adjusted net present value (rNPV)

Risk-adjusted net present value (rNPV) is considered the gold standard for biotech valuation. It offers a more sophisticated approach than traditional NPV calculations.

This method analyzes potential returns by incorporating success probabilities at various development stages. The process involves calculating potential future cash flows, adjusting them based on the likelihood of reaching specific milestones, and then discounting these risk-adjusted values to present day.

To illustrate, consider a drug with a $1 billion market potential. If it has only a 10% chance of receiving regulatory approval, its rNPV might be $100 million before time-based discounting is applied.

The key is assigning accurate probability rates. Industry benchmarks suggest:

• Preclinical to Phase 1: 35% success rate

• Phase 1 to Phase 2: 63% success rate

• Phase 2 to Phase 3: 31% success rate

• Phase 3 to approval: 58% success rate

• Overall success rate (Preclinical to approval): About 4%

❗The success rates don't follow a linear progression since each stage evaluates different aspects of scientific merit, safety, and efficacy. Clearing one stage doesn't guarantee success in the next - quite the opposite. Later stages present even more rigorous challenges that eliminate many drug candidates.

❗️These probabilities vary significantly by therapeutic area. Oncology drugs typically have lower success rates than infectious disease treatments, while rare disease therapies often see higher success rates due to streamlined regulatory pathways.

2. Comparable company analysis

This approach looks at valuation benchmarks for similar biotech companies at comparable stages of development.

Key metrics include:

• Value per program in pipeline

• Enterprise value based on development stage

• Deal values for similar assets in partnerships or acquisitions

For instance, a Series A biotech company working on a novel antibody platform might compare itself to other antibody platform companies that raised funding in the last 2-3 years.

The challenge here is finding truly comparable companies given the unique nature of each biotech's technology, target, and approach.

Interestingly, European biotech valuations typically lag behind US counterparts by 30-50% for comparable companies, creating regional valuation disparities that investors should consider.

3. Venture capital method

With this approach, investors work backwards from a desired return on investment:

1. Estimate the company's exit value at a future date (often 5-7 years)

2. Determine the ownership percentage needed to achieve the target return (typically 10-15x for early-stage biotech)

3. Calculate the current post-money valuation based on that ownership target

Many VC firms targeting biotech investments aim for a portfolio return of 3-5x, knowing that many investments will fail, but successful ones should deliver 10x+ returns.

4. Real options valuation

This sophisticated approach treats each development decision as an "option" with specific costs and potential values.

For example, the decision to advance from Phase 2 to Phase 3 trials represents an option that management can exercise based on data. This method captures the value of flexibility in decision-making that traditional valuation methods might miss.

🔍 CASE STUDY: BioNTech – From lab to global impact

Before becoming a household name during the COVID-19 pandemic, BioNTech's valuation journey illustrates the challenges and opportunities in biotech valuation.

Founded in 2008 in Mainz, Germany, BioNTech spent over a decade as a relatively obscure biotech focused on mRNA therapeutics for cancer. Despite its innovative technology platform, its early funding rounds valued the company at modest levels compared to US counterparts.

Key valuation inflection points:

• 2018: €270 million Series A at approximately €2.4 billion valuation

• 2019: IPO raising $150 million, valuing the company at ~$3.4 billion

• Early 2020: Trading at ~$30/share (market cap around $7 billion)

• December 2020: Following COVID vaccine success, reached $120/share (~$29 billion)

• August 2021: Peak of $447/share (~$108 billion)

What makes BioNTech's case fascinating is how dramatically investor perception shifted. The core technology platform remained largely unchanged, but the validation of their mRNA approach through the COVID vaccine completely transformed the risk assessment of their entire pipeline.

This case demonstrates how binary outcomes can create enormous valuation swings, the value of platform technologies that can address multiple indications, and how external events can dramatically accelerate timelines in biotech.

Valuation across development stages

Biotech valuations typically follow this progression:

• Preclinical stage: $10-30 million: Value driven by novelty, science quality, and team experience

• Phase 1: $50-100 million: Value driven by safety data and early efficacy signals

• Phase 2: $100-500 million: Value driven by efficacy data and market opportunity

• Phase 3: $250 million-$1+ billion: Value driven by approval probability and commercial potential

Most analysts validate these theoretical valuations against market reality – what investors have historically paid for comparable companies or recent deal terms for similar assets.

Key factors influencing valuation

Several factors significantly impact valuation beyond just development stage:

📊 Therapeutic area & market potential: Oncology and rare disease companies often command 30-50% higher valuations due to high unmet need, premium pricing potential, and strong acquisition interest.

🗄️ Patent position & intellectual property: Companies with composition-of-matter patents typically secure higher valuations than those with method-of-use patents or less comprehensive IP protection.

🛟 Management team credibility: For therapeutics companies, management expertise is important but team changes are expected over the long development timeline. For non-therapeutics, team stability is more crucial for valuation, reflecting the importance of execution over a shorter timeframe.

🤝🏻 Strategic partnerships: Deals with established pharmaceutical companies provide powerful external validation. A significant partnership can instantly double or triple a biotech's valuation without any change in the underlying science.

🔮 Emerging trends in biotech valuation

Several trends are changing how biotech companies are valued:

AI-accelerated drug discovery: Companies leveraging AI in drug discovery are securing valuations 1.5-2x higher than traditional discovery companies, with AI biotech hubs emerging in the UK, Switzerland, China, and Singapore alongside US centers. The promise of faster, cheaper development and potentially higher success rates is driving this premium.

The "platform premium": Companies with platform technologies that can generate multiple drug candidates command higher valuations (often 1.5-2x) than single-product companies. This reflects the reduced binary risk and greater potential for multiple successful products.

Public market premium: Public market valuations for biotech companies typically command a 30% premium over private market valuations for comparable companies, driving the IPO strategy for many therapeutics companies.

Alternative financing models: New funding structures are emerging to address biotech's unique risk profile:

• Structured financings: Tying investment to specific milestones

• Royalty financing: Selling future revenue streams for upfront capital

• Platform spinouts: Creating separate companies for different applications of core technology

• Public-private partnerships: Particularly important for biotechs in emerging markets

These approaches often allow for higher overall valuations while aligning investor exposure more precisely with specific assets or milestones.

Final thoughts

So, there you have it!

I've come to realize that despite all the fancy valuation models and spreadsheets, there's still an art to valuing biotech companies. Even the most detailed financial models depend on educated guesses about whether the science will work, whether regulators will approve it, and whether doctors will actually use it.

For my fellow entrepreneurs out there, I can't stress enough how important it is to understand these valuation methods. They're not just numbers - they're tools that can help you tell your story better and raise money more effectively.

At the end of the day, I find it fascinating how these complex financial calculations help turn groundbreaking science into real treatments that help real people. It's a reminder that behind all the spreadsheets and pitch decks, we're working toward something that truly matters.

Find out why 1M+ professionals read Superhuman AI daily.

In 2 years you will be working for AI

Or an AI will be working for you

Here's how you can future-proof yourself:

1. Join the Superhuman AI newsletter – read by 1M+ people at top companies

2. Master AI tools, tutorials, and news in just 3 minutes a day

3. Become 10X more productive using AI

Join 1,000,000+ pros at companies like Google, Meta, and Amazon that are using AI to get ahead.

Sign up and start learning AI

Weird and wonderful

❄️ Frozen Fatherhood: Scientists have performed a first-of-its-kind procedure transplanting sperm-making stem cells into a man who had his cells preserved before childhood cancer treatment. Imagine the journey these tiny cells have been on - frozen as a child, thawed as an adult, and now potentially swimming toward fatherhood! While no sperm have appeared yet, researchers remain hopeful. If successful, this could revolutionize fertility options for cancer survivors.

🦖🐔 Jurassic Squawk: Scientists have created dinosaur chickens by messing with one feather gene, and the birds are not amused! By turning off the appropriately named "sonic hedgehog pathway", researchers transformed modern poultry into prehistoric-looking creatures with unbranched, primitive feathers. These accidental time travelers sport the same simple rod-like coverings their ancestors wore millions of years ago, giving chickens the ultimate evolutionary throwback look. While the birds eventually grew their fancy modern feathers back, for a brief moment, they were strutting around, looking like they might start hunting Jeff Goldblum.

Thank you for reading the Healthy Innovations newsletter!

Keep an eye out for next week’s issue, where I will highlight the healthcare innovations you need to know about.

Have a great week!

Alison ✨

P.S. If you enjoyed reading the Healthy Innovations newsletter, please subscribe so I know the content is valuable to you!

P.P.S. Healthcare is evolving at an unprecedented pace, and your unique insights could be invaluable to others in the field. If you're considering starting your own newsletter to share your expertise and build a community around your healthcare niche, check out beehiiv (affiliate link). There's never been a better time to start sharing your knowledge with the world!